Document:

Exhibit
10.1

 

PREFERRED
STOCK PURCHASE AGREEMENT

 

This
Preferred Stock Purchase Agreement (this “Agreement”) is made as of May 22, 2020, by and among Gene Biotherapeutics,
Inc. a Delaware corporation with its principal office at 11230 Sorrento Valley Road Suite #220, San Diego, CA 92122 (“CRXM”
or the “Company”) and Nostrum Pharmaceuticals, LLC Delaware limited liability company with its principal office
at 1370 Hamilton Street Somerset NJ, 08873 (“NPLLC” or the “Purchaser”).

 

RECITALS

 

A.
The Company has authorized the sale and issuance to the Purchaser of 1,700,000 shares (the “Shares”) of Series
B Convertible Preferred Stock, $0.0001 par value per share, of the Company (the “Series B Preferred Stock”),
in a private placement pursuant to an exemption from the registration requirements of Section 5 of the Securities Act (as defined
below) contained in Section 4(a)(2) thereof and/or Regulation D thereunder.

 

B.
The Company has created the Series B Preferred Stock by filing a Certificate of Designation of Preferences, Rights and Limitations
relating to the Series B Preferred Stock (the “Series B Certificate of Designation”) with the Secretary of
State of the State of Delaware in substantially the form annexed hereto as Exhibit A, prior to the execution and
delivery of this Agreement. The Shares will be convertible into shares of common stock, $0.0001 par value per share, of the Company
(the “Common Stock”) at an initial conversion ratio of .0113 and will have the other designations, relative
rights, preferences and limitations set forth in the Series B Certificate of Designation.

 

C.
The Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, the Shares on the terms
and subject to the conditions set forth in this Agreement.

 

TERMS
AND CONDITIONS

 

Now,
therefore, in consideration of the foregoing recitals and the mutual covenants and agreements contained herein, the parties, intending
to be legally bound, do hereby agree as follows:

 

1.
Definitions and Interpretive Principles.

 

1.1
Definitions.
Capitalized terms used in this Agreement, and not otherwise defined herein, shall have the meanings ascribed to such terms in
Schedule A.

 

1.2
General Interpretive Principles.
Whenever used in this Agreement, except as otherwise expressly provided or unless the context otherwise requires, any noun or
pronoun shall be deemed to include the plural as well as the singular and to cover all genders. The name assigned this Agreement
and the section captions used herein are for convenience of reference only and shall not be construed to affect the meaning, construction
or effect hereof. Whenever the words “include,” “includes,” or “including” are used in this
Agreement, they shall be deemed to be followed by the words “without limitation.” Unless otherwise specified, the
terms “hereto,” “hereof,” “herein” and similar terms refer to this Agreement as a whole (including
the exhibits, schedules and disclosure statements hereto), and references herein to Articles or Sections refer to Articles or
Sections of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto
to express their mutual intent, and no rule of strict construction shall be applied against any Person.

 

    	-1-

     

    

 

2.
Purchase of the Shares.

 

2.1
Agreement to Sell and Purchase.
At the Closing (as hereinafter defined), the Company will issue and sell to the Purchaser, and the Purchaser will purchase from
the Company, the Shares for an aggregate purchase price of $1,700,000 (the “Purchase Price”) or $1.00 for each
Share.

 

2.2
Closing; Closing Date.
The completion of the sale and purchase of the Shares (the “Closing”) shall be held simultaneously with the
execution and delivery of this Agreement, or at such other time as the Company and the Purchaser may agree (the “Closing
Date”).

 

2.3
Delivery of the Shares.
At the Closing, subject to the terms and conditions hereof, the Company will deliver to the Purchaser a stock certificate or certificates
dated the Closing Date representing the Shares, in such denominations and registered in such name(s) as the Purchaser may designate
by written notice to the Company, (each such certificate is hereinafter referred to as a “Certificate”), against
payment of the Purchase Price in cash in the form of a wire transfer to a bank designated in writing by the Company, unless other
means of payment shall have been agreed upon by the Purchaser and the Company.

 

3.
Representations and Warranties of the Company. The Company hereby represents and warrants to the Purchaser the following:

 

3.1
Authorization.
All corporate action on the part of the Company, its officers, directors and shareholders necessary for the authorization, execution,
delivery and performance of this Agreement and the transactions contemplated hereby including the authorization and filing of
the Series B Certificate of Designation has been taken. The Company has heretofore received from its shareholders all required
approvals necessary for the Company’s execution, delivery and performance of its obligations under this Agreement and the
transactions contemplated hereby including the authorization and filing of the Series B Certificate of Designation. The Company
has the requisite corporate power to enter into this Agreement and carry out and perform its obligations under this Agreement.
At the Closing, the Company will have the requisite corporate power to issue and sell the Shares. This Agreement has been duly
authorized, executed and delivered by the Company and, upon due execution and delivery by the Purchaser, this Agreement will be
a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as rights to
indemnity hereunder may be limited by federal or state securities laws and except as enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by equitable principles.

 

3.2
Valid Issuance; Reservation of Conversion
Shares. The Shares, when issued, sold and delivered in accordance
with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and
free from all taxes, liens, claims, encumbrances and charges with respect to the issue thereof; provided, however, that the Shares
will be subject to restrictions on transfer under state and/or federal securities laws. The Conversion Shares, when issued and
delivered in accordance with the terms of the Series B Certificate of Designation will be validly issued, fully paid and nonassessable
and free from all taxes, liens, claims, encumbrances and charges with respect to the issue thereof; provided, however, that the
Securities will be subject to restrictions on transfer under state and/or federal securities laws. Prior to the Closing, the Company
will have filed with the Secretary of State of the State of Delaware, the Series B Certificate of Designation. The Company will,
at all times while the Shares are outstanding, reserve for issuance a sufficient number of shares of Common Stock to accommodate
the conversion in full of the then outstanding Shares. Not less than 150,442,478 shares of Common Stock have been duly reserved
for issuance upon the conversion of the Shares.

 

    	-2-

     

    

 

3.3
No Conflict with Other Instruments.
Except as set forth on Schedule 3.3, the execution, delivery and performance of this Agreement, the issuance and sale of
the Shares to be sold by the Company hereunder and the consummation of the actions contemplated by this Agreement will not (A)
result in any violation of, be in conflict with, or constitute a default under, with or without the passage of time or the giving
of notice of: (i) any provision of the Company’s charter documents as in effect on the date hereof (as amended to include
the Series B Certificate of Designation ); (ii) any provision of any Governmental Order to which the Company or any of its Subsidiaries
are a party or by which they are bound; (iii), any bond, debenture, note or other evidence of indebtedness, or any lease, contract,
mortgage, indenture, deed of trust, loan agreement, joint venture or other agreement, instrument or commitment to which the Company
or any Subsidiary is a party or by which they or their respective properties are bound; or (iv) any Law applicable to the Company
or any of its Subsidiaries; or (B) result in the creation or imposition of any Encumbrance upon any of the properties or assets
of the Company or any of its Subsidiaries or any acceleration of indebtedness pursuant to any obligation, agreement or condition
contained in any bond, debenture, note or any other evidence of indebtedness or any indenture, mortgage, deed of trust or any
other agreement or instrument to which the Company or any of its Subsidiaries are a party or by which they are bound or to which
any of the property or assets of the Company or any Subsidiary is subject. No consent, approval, authorization or other order
of, or registration, qualification or filing with, any regulatory body, administrative agency, or other governmental body is required
for the execution and delivery of this Agreement by the Company and the valid issuance or sale of the Securities by the Company
pursuant to this Agreement, except for the filing of the Series B Certificate of Designation with the Delaware Secretary of State
and the filing of a Form D or similar limited offering exemption form under applicable federal and state securities laws.

 

3.4
Certificate of Incorporation; Bylaws.
The Company has made available to the Purchaser true, correct
and complete copies of the Certificate of Incorporation and Bylaws of the Company, as in effect on the date hereof.

 

3.5
Organization, Good Standing and Qualification.
The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its
business as now conducted. The Company and each of its Subsidiaries has full power and authority to own, operate and occupy its
properties and to conduct its business as presently conducted and is duly qualified to transact business and is in good standing
in each jurisdiction where the ownership of its properties or conduct of its business makes such qualification to transact business
necessary, except where the failure to be so qualified would not materially and adversely affect the business, operations or financial
condition of the Company.

 

    	-3-

     

    

 

3.6
SEC Filings.
The Company currently is, and since August 14, 2017 has been, delinquent with its filings with the SEC. As used herein, the “Company
SEC Documents” means all reports, schedules, forms, statements and other documents filed or furnished, as applicable,
by the Company under the Securities Act and/or the Exchange Act prior to August 14, 2017. None of the Company SEC Documents, when
filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein in light of the circumstances under which they were made not misleading.

 

3.7
Financial Statements; Settlement of Claims.

 

(a)
Complete copies of (i) the Company’s
unaudited financial statements consisting of the balance sheet of the Company as at December 31 in each of the years 2018 and
2017 and the related statements of operations and cash flow for the years then ended (the “Annual Financial Statements”)
and (ii) the Company’s unaudited financial statements consisting of the balance sheet of the Company as at May 31, 2019
and the related statement of income for the five (5) months then ended (the “Interim Financial Statements”
and, together with the Annual Financial Statements, the “Financial Statements”). The Financial Statements are
attached to Schedule 3.7(a). The balance sheet of the Company as of May 31, 2019 is referred to herein as the “Balance
Sheet” and the date thereof as the “Balance Sheet Date”. The Financial Statements: (i) were prepared
from the books and records of the Company; and (ii) fairly present the consolidated financial position of the Company and its
Subsidiaries as of the respective dates thereof and the consolidated results of operations and cash flows of the Company and its
Subsidiaries for the periods covered thereby.

 

(b)
Schedule 3.7(b) sets forth a correct
and complete list of all creditor claims against the Company.

 

(c)
Schedule 3.7(c) sets forth a correct
and complete list of all claims by employees and former employees of the Company for accrued and unpaid deferred salary.

 

3.8
Books and Records. The
books, records and accounts of the Company and its subsidiaries accurately and fairly reflect, in reasonable detail, the transactions
in, and dispositions of, the assets of, and the operations of, the Company and its subsidiaries.

 

3.9
Capitalization.
The authorized capital stock of the Company, consists of (i) 200,000,000 shares of Common Stock of which (A) 14,489,399 shares
are issued and outstanding as of the date of this Agreement, and (B) 19,188,222 shares are reserved for issuance upon the exercise
or conversion, as the case may be, of the options, warrants or other convertible securities outstanding as of the date of this
Agreement which are set forth on Schedule 3.9; and (ii) 40,000,000 shares of Preferred Stock, of which 790 shares of Series
A Preferred Stock are issued and outstanding as of the date of this Agreement and no shares of Series A Preferred Stock are reserved
for issuance as of the date of this Agreement. Schedule 3.9 sets forth, for each Subsidiary of the Company, the amount
of its authorized capital stock or other equity or ownership interests, the amount of its outstanding capital stock or other equity
or ownership interests, and the record and beneficial owners of its outstanding capital stock or other equity or ownership interests.
All issued and outstanding shares of capital stock of the Company and each Subsidiary has been duly authorized and validly issued,
are fully paid and non-assessable, have been issued and sold in compliance with the registration requirements of the federal and
state securities laws, and were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. Except as set forth on Schedule 3.9, there are no (i) outstanding rights (including, without limitation, preemptive
rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued shares of capital stock
or other equity interest in the Company or any Subsidiary, or any contract, commitment, agreement, understanding or arrangement
of any kind to which the Company or any Subsidiary is a party and relating to the issuance or sale of any capital stock or convertible
or exchangeable security of the Company or any Subsidiary; or (ii) obligations of the Company or any Subsidiary to purchase redeem
or otherwise acquire any of its outstanding capital stock or any interest therein or to pay any dividend or make any other distribution
in respect thereof. Except as set forth on Schedule 3.9, there are no anti-dilution or price adjustment provisions, co-sale
rights, registration rights, rights of first refusal or other similar rights contained in the terms governing any outstanding
security of the Company that will be triggered by the issuance of the Securities and no person has any right to cause the Company
to effect the registration under the Securities Act of any securities of the Company. No shares of capital stock or other equity
or ownership interests of the Company or any of its Subsidiaries have been issued in violation of any rights, agreements, arrangements
or commitments under any provision of applicable Law, the certificate of incorporation or bylaws or equivalent organizational
documents of the Company or any of its Subsidiaries or any contract to which the Company or any of its Subsidiaries is a party
or by which the Company or any of its Subsidiaries is bound.

 

    	-4-

     

    

 

3.10
Subsidiaries.
Each Subsidiary of the Company is duly incorporated or organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation or organization and has all requisite power and authority to carry on its business as now conducted.
Each Subsidiary of the Company is duly qualified to transact business and is in good standing in each jurisdiction where the ownership
of its properties or conduct of its business makes such qualification to transact business necessary, except where the failure
to be so qualified would not materially and adversely affect the business, operations or financial condition of the Company. Except
for the Company’s ownership interest in the Subsidiaries, neither the Company nor any of its Subsidiaries directly or indirectly
owns any equity, partnership, membership or similar interest in, or any interest convertible into, exercisable for the purchase
of or exchangeable for any such equity, partnership, membership or similar interest, or is under any current or prospective obligation
to form or participate in, provide funds to, make any loan, capital contribution or other investment in or assume any liability
or obligation of, any Person. The Company has made available to the Purchaser true, correct and complete copies of the charter,
bylaws or other organizational documents of each Subsidiary, as in effect on the date hereof.

 

3.11
Title to Assets. The
Company has good and marketable title to all of the assets and properties which it purports to own including those assets and
properties which are reflected on the Financial Statements, free and clear of all encumbrances, except for (a) liens for current
taxes not yet due and payable or for taxes the validity of which is being contested in good faith by appropriate proceedings,
and (b) encumbrances which individually or in the aggregate do not materially and adversely affect the business, operations or
financial condition of the Company.

 

3.12
 No Preemptive Rights.
The issuance, sale and delivery of the Shares in accordance with the terms hereof and the issuance, sale and delivery of the Conversion
Shares in accordance with the terms of the Series B Certificate of Designation will not be subject to preemptive rights of shareholders
of the Company.

 

3.13
Offering.
Assuming the accuracy of the representations of the Purchaser in this Agreement on the date hereof, the offer, issue and sale
of the Securities are and will be exempt from the registration and prospectus delivery requirements of the Securities Act. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers
or sales of any security or solicited any offers to buy any security under circumstances that would require registration under
the Securities Act of the issuance of the Securities to the Purchaser. The Company has not taken any action to sell, offer for
sale or solicit offers to buy any securities of the Company which would bring the offer, issuance or sale of the Securities within
the provisions of Section 5 of the Securities Act, unless such offer, issuance or sale was or shall be within the exemptions of
Section 4 of the Securities Act.

 

3.14
Contracts.
Except as set forth on Schedule 3.14, neither the Company nor any Subsidiary is a party to any Contract.

 

3.15
Litigation; Governmental Orders.
Except as set forth on Schedule 3.15, (a) there are no Actions pending or, to the Company’s Knowledge, threatened
against or by the Company or any of its Subsidiaries affecting any of their properties or assets (or by or against the Company,
its Subsidiaries or any Affiliate thereof and relating to the Company or its Subsidiaries), and (b), no event has occurred or
circumstances exist that may give rise to, or serve as a basis for, any such Action. There are no outstanding Governmental Orders
and no unsatisfied judgments, penalties or awards against or affecting the Company, any of its Subsidiaries or any of their properties
or assets.

 

3.16
Compliance with Laws.
Neither the Company nor any of its Subsidiaries is in violation of its Certificate of Incorporation or Bylaws (or similar organizational
documents). Except as set forth on Schedule 3.16, the Company and its Subsidiaries currently are, and in the past have
been, conducting their business in compliance with all applicable Laws. Each of the Company and its Subsidiaries has all Permits
necessary for the operation of the business of the Company and its Subsidiaries as currently conducted.

 

3.17
No Material Changes.
Since December 31, 2018, there has been no material adverse change in the assets, liabilities, business, properties, operations,
financial condition or results of operations of the Company or any of its Subsidiaries.

 

3.18
Undisclosed Liabilities. The
Company has no Liabilities except (a) those which are adequately reflected or reserved against in the Balance Sheet as of the
Balance Sheet Date, and (b) those which have been incurred in the ordinary course of business consistent with past practice of
the Company since the Balance Sheet Date and which are not, individually or in the aggregate, material in amount.

 

    	-5-

     

    

 

3.19
Transactions With Affiliates.
Except as set forth on Schedule 3.19, there are no Contracts or other transactions between or among (i) the Company
or any of its Subsidiaries, on the one hand, and (ii) any officer, director, employee or present or former stockholder of the
Company or any of its Subsidiaries (including any spouse, parent, sibling or descendants of any such natural persons, or trust
or other entity in which any such natural persons or such other individuals owns or otherwise holds any beneficial interest in)
or Affiliate of the Company, on the other hand.

 

3.20
Intellectual Property.

 

(a)
The Company and each of its Subsidiaries
has ownership or license or legal right to use, all patent, copyright, trade secret, know-how trademark, trade name customer lists,
designs, manufacturing or other processes, computer software, systems, data compilation, research results or other proprietary
rights set forth on Schedule 3.20(a) (collectively “Intellectual Property”).

 

(b)
The Company and each of its Subsidiaries
has taken all reasonable steps required in accordance with sound business practice and business judgment to establish and preserve
its ownership of the Intellectual Property.

 

(c)
To the Knowledge of the Company, the Intellectual
Property does not infringe any intellectual property of any other Person. To the Knowledge of the Company, no other Person is
infringing any rights of the Company or its Subsidiaries to the Intellectual Property.

 

(d)
No Actions are pending or, to the Knowledge
of the Company, threatened, which challenge the rights of the Company or any of its Subsidiaries to the use of the Intellectual
Property. Except with respect to the licensed Intellectual Property identified on Schedule 3.20(f), the Company and each
of its Subsidiaries is the exclusive owner of each item of Intellectual Property and has the right to use, free and clear of material
claims or rights of other Persons, all of its Intellectual Property. Each item of Intellectual Property is validly existing and
in full force and effect and will be validly existing and in full force and effect immediately following the Closing.

 

(e)
Neither the Company nor any of its Subsidiaries
is making unauthorized use of any confidential information or trade secrets of any Person. The activities of any of the employees
or former employees on behalf of the Company or of any of its Subsidiaries do not violate and have not violated any Contracts
or arrangements between such employees or former employees and third parties related to confidential information or trade secrets
of third parties or that restrict any such employee’s engagement in business activity of any nature.

 

(f)
Schedule 3.20(f) sets forth a true
and complete list of all licenses or other agreements under which (i) the Company or any Subsidiaries employs rights in Intellectual
Property, or (ii) the Company or any Subsidiaries has granted rights to others in Intellectual Property owned or licensed by the
Company or any Subsidiaries. All of the licenses or other agreements set forth on Schedule 3.20(f), are in full force and
effect, and there is no default and there exists no condition which, with the passage of time or otherwise, would constitute a
default by the Company or any Subsidiaries of the Company with respect thereto.

 

    	-6-

     

    

 

3.21
Taxes.
The Company and each of its Subsidiaries has filed all federal, state, local and foreign income and franchise tax returns and
has paid all taxes shown as due thereon through the calendar year ended December 31, 2017. The Company has incurred significant
net operating losses to date. The Company does not owe any federal, state, local or foreign income taxes for any period after
December 31, 2017.

 

3.22
Transfer Taxes.
On the Closing Date, all stock transfer or other taxes (other than income taxes) that are required to be paid in connection with
the sale and transfer of the Securities hereunder will be, or will have been, fully paid or provided for by the Company and the
Company will have complied with all laws imposing such taxes.

 

3.23
Investment Company.
The Company (including its Subsidiaries) is not an “investment company” or an “affiliated person” of,
or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment
Company Act of 1940 and will not be deemed an “investment company” as a result of the consummation of the transactions
contemplated by this Agreement.

 

3.24
Foreign Corrupt Practices.
Neither the Company nor any of its Subsidiaries nor any director, officer, agent, employee or other Person acting on behalf of
the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its Subsidiaries
(i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate
funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977; or (iv) made any
unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official
or employee.

 

3.25
Regulatory Compliance.

 

(a)
The Company has obtained a Fast Track designation
for the Phase 3 clinical investigation of Generx (Ad5FGF-4) cardiovascular angiogenic gene therapy (“Generx”).

 

(b)
The Company and Angionetics, Inc. are in
compliance with all FDA and similar state and local requirements applicable to (i) the testing and development of Generx and (ii)
maintenance, compilation and filing of reports with regard to Generx.

 

(c)
All of the studies and tests in relation
to Generx conducted by or on behalf of Company and Angionetics, Inc. were, or are being, conducted in accordance with applicable
Laws and in accordance with the prevailing scientific standards applicable to the conduct of such studies and activities. All
required pre-clinical toxicology studies and non-clinical laboratory studies sponsored by or on behalf of Company, Angionetics,
Inc. or otherwise conducted with respect to Generx have been, or are being, conducted in compliance with the FDA’s Good
Manufacturing Practices, Good Laboratory Practices and Good Clinical Practices in the United States. Each clinical trial conducted
by or on behalf of Company and Angionetics, Inc. with respect to Generx was, or is being, conducted in accordance with its clinical
trial protocol, and in compliance with all applicable Laws and Company has filed all required notices (and made available to Purchaser
copies thereof) of adverse drug or product experiences, injuries or deaths relating to clinical trials conducted by or on behalf
of Company and Angionetics, Inc. with respect to Generx.

 

    	-7-

     

    

 

(d)
The Company and Angionetics, Inc. are in
compliance with all applicable reporting requirements, including applicable adverse event reporting requirements under applicable
Law. All filings with and submissions to the FDA made by the Company and Angionetics, Inc. with regard to Generx were true, accurate
and complete in all material respects as of the date made, and, to the extent required to be updated, as so updated remain true,
accurate and complete in all material respects as of the date hereof and do not materially misstate any of the statements or information
included therein, or omit to state a material fact necessary to make the statements therein not misleading. The Company has heretofore
made available to the Purchaser correct and complete copies of all correspondence, filings and reports between the Company and
the FDA with respect to Generx.

 

(e)
The Company has not received any notice from
the FDA alleging any violation of any Laws or Permits by the Company, or taking or threatening to take, any action to suspend
clinical trials of Generx, or otherwise restrict the research or clinical study of Generx. There have been no adverse regulatory
actions taken (or, to the Knowledge of the Company, threatened) by the FDA with respect to Generx. To Company’s Knowledge,
there is no act, omission, event or circumstance that would reasonably be expected to give rise to any such actions.

 

(f)
None of the Company nor its directors, officers,
employees, agents, representatives or consultants are under investigation by the FDA.

 

(g)
The Company has provided to the Purchaser
correct and complete copies of all information relating to adverse drug experiences obtained or otherwise received by the Company
or Angionetics, Inc. from any source with respect to Generx.

 

3.26
Takeover Statutes. The
Board has taken all actions necessary so that the restrictions contained in Section 203 of the DGCL applicable to a “business
combination” (as defined in Section 203) shall not apply to the transactions contemplated by this Agreement including the
issuance of the Shares to the Purchaser and, to Company’s Knowledge, no other “fair price”, “moratorium”,
“control share acquisition” or other similar anti-takeover law (collectively, “Takeover Laws”)
are applicable to transactions between Purchaser and the Company.

 

3.27
No Brokers.
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with
the transactions contemplated by this Agreement based on arrangements made by the Company.

 

3.28
Full Disclosure.
No representation or warranty by the Company in this Agreement and no statement contained in the Schedules to this Agreement or
any certificate or other document furnished or to be furnished to Purchaser pursuant to this Agreement contains any untrue statement
of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances
in which they are made, not misleading. To the Knowledge of the Company, there is no event or circumstance that the Company has
not disclosed to Purchaser which could reasonably be expected to have a material adverse change in the assets, liabilities, business,
properties, operations, financial condition or results of operations of the Company or any of its Subsidiaries.

 

    	-8-

     

    

 

4.
Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company the following:

 

4.1
Organization, Good Standing and Qualification.
The Purchaser is a limited liability company duly organized,
validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority
to carry on its business as now conducted.

 

4.2
Due Execution.
All company action on the part of the Purchaser, its officers, directors and members necessary for the authorization, execution,
delivery and performance of this Agreement has been taken. The Purchaser has the requisite corporate power to enter into this
Agreement and carry out and perform its obligations under this Agreement. This Agreement has been duly authorized, executed and
delivered by the Purchaser and, upon due execution and delivery by the Company, this Agreement will be a valid and binding agreement
of the Purchaser, enforceable against the Purchaser in accordance with its terms, except as rights to indemnity hereunder may
be limited by federal or state securities laws and except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ rights generally or by equitable principles.

 

4.3
No Conflict with Other Instruments.
The execution, delivery and performance of this Agreement and the consummation of the actions contemplated by this Agreement will
not (A) result in any violation of, be in conflict with, or constitute a default under, with or without the passage of time or
the giving of notice of: (i) any provision of the Purchaser’s charter documents as in effect on the date hereof; (ii) any
provision of any Governmental Order to which the Purchaser is a party or by which it is bound; (iii) any bond, debenture, note
or other evidence of indebtedness, or any lease, contract, mortgage, indenture, deed of trust, loan agreement, joint venture or
other agreement, instrument or commitment to which the Purchaser is a party or by which its properties are bound; or (iv) any
Law applicable to the Purchaser. No consent, approval, authorization or other order of, or registration, qualification or filing
with, any Governmental Authority is required for the execution and delivery of this Agreement by the Purchaser.

 

4.4
No Brokers. No
broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with
the transactions contemplated by this Agreement based on arrangements made by the Purchaser.

 

4.5
Investment Representations.
In connection with the sale and issuance of the Securities, the Purchaser makes the following representations:

 

(a)
Investment for Own Account.
The Purchaser is acquiring the Securities for its own account, not as nominee or agent, and not with a view to, or for resale
in connection with, any distribution or public offering thereof within the meaning of the Securities Act; provided, however, that
by making the representations herein, the Purchaser does not agree to hold any of the Securities for any minimum or specific term
and reserves the right to dispose of the securities at any time in accordance with or pursuant to a registration statement or
an exemption from the registration requirements of the Securities Act.

 

    	-9-

     

    

 

(b)
Financial Sophistication; Due Diligence.
The Purchaser is familiar with the term “accredited investor”
as defined in Rule 501(a) of Regulation D promulgated under the Securities Act and is an “accredited investor” within
the meaning of such term. The Purchaser has such knowledge and experience in financial or business matters that it is capable
of evaluating the merits and risks of the investment in connection with the transactions contemplated in this Agreement. The Purchaser
has, in connection with its decision to purchase the Securities, relied only upon the representations and warranties contained
herein. Further, the Purchaser has had such opportunity to obtain additional information and to ask questions of, and receive
answers from, the Company, concerning the terms and conditions of the investment and the business and affairs of the Company,
as the Purchaser considers necessary in order to form an investment decision.

 

5.
Closing Deliverables.

 

5.1
Closing Deliverables of the Company.
At the Closing, the Company shall deliver to Purchaser the following:

 

(a)
the Certificate(s);

 

(b)
a copy of resolutions adopted by the Board,
certified by the Secretary of the Corporation, authorizing this Agreement and issuance of the Shares and appointing James Grainer
and Kaushik Vyas as directors of the Company;

 

(c)
evidence of filing of the Series B Certificate
of Designation with the Secretary of State of the State of Delaware substantially in the form of Exhibit A attached
hereto.;

 

(d)
an opinion of legal counsel to the Company,
dated as of the Closing Date, substantially in the form Exhibit B attached hereto;

 

(e)
a letter executed by each creditor of the
Company agreeing to settle the amount of such creditor’s claim against the Company for the settlement amount set forth on
Schedule 3.7(b) on the terms and conditions substantially in the form of Exhibit C annexed hereto;

 

(f)
a letter executed by each employee and former
employee of the Company agreeing to defer such employee’s or former employee’s claim for accrued and unpaid deferred
salary from the Company (all such letters are included in Exhibit D annexed hereto);

 

(g)
a letter executed by each holder of Company
warrants or options agreeing to waive any rights to anti-dilution adjustment with respect to such warrants or options as a result
of the issuance and sale of the Securities to the Purchaser (all such letters are included in Exhibit E annexed
hereto);

 

(h)
letters from Leitch, Wallace, Zhang and Zhang
resigning as officers and directors of the Company effective at the Closing Date;

 

    	-10-

     

    

 

(i)
a Reaffirmation and Ratification Agreement
between the Company and Shanxi Taxus Pharmaceuticals Co., Ltd. (Exhibit F-1 annexed hereto with respect to cancellation
of the issuance of shares of Common Stock in consideration of $600,000 previously paid by Shenzhen Qianhai Taxus to the Company);

 

(j)
a Distribution and License Agreement between
Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd., (Exhibit F-2 annexed hereto with respect to the Generx
product candidate);

 

(k)
Amendment No.1 to Distribution and License
Agreement between Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd., (Exhibit F-3 annexed hereto with
respect to the Generx product candidate);

 

(l)
a License and Patent Assignment Agreement
between Activation Therapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd., (Exhibit F-4 with respect to the
Excellagen product);

 

(m)
agreements with New York University and the
University of California settling the amount of each such creditor’s claim against the Company for the amounts set forth
on Exhibit C and otherwise on the terms and conditions contained in the form of Exhibit G annexed hereto;

 

(n)
a good standing certificate (or its equivalent)
from the Secretary of State of the State of Delaware for the Company and each of its Subsidiaries; and

 

(o)
a duly executed counterpart of this Agreement.

 

5.2
Closing Deliverables of the Purchaser.
At the Closing, the Purchaser shall deliver to Company the following::

 

(a)
payment of the Purchase Price in cash in
the form of a wire transfer; and

 

(b)
a duly executed counterpart of this Agreement.

 

6.
Additional Covenants.

 

6.1
SEC Filings. The
Company has engaged Marcum, LLP (“Marcum”) to prepare the Company’s financial statements for the years
ended December 31, 2017, 2018 and 2019 that are required to be filed with Securities and Exchange Commission (“SEC”)
pursuant to the Exchange Act in order to cause the Company to become current with its reporting obligations. The expense incurred
for such financial statement preparation, up to $120,000, will be paid by the Company from the proceeds of the sale of the Shares.
It is understood that the Company is delinquent in its SEC reporting obligations and the Company and its officers and directors
shall use their reasonable best efforts to assist Marcum so as to ensure that the Company becomes current with such obligations.
Within four (4) Business Days after the Closing, the Company will file a current report on Form 8-K disclosing the change of control
contemplated by this Agreement.

 

    	-11-

     

    

 

6.2
Further Assurances. Following
the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional
documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the
provisions hereof and give effect to the transactions contemplated by this Agreement.

 

7.
Indemnification.

 

7.1
Survival.
The representations and warranties, covenants and agreements contained herein shall survive the Closing and shall remain in full
force and effect following the Closing Date. Notwithstanding the preceding sentence, any representation or warranty in respect
of which indemnity may be sought under this Agreement shall survive the time at which it would otherwise terminate pursuant to
the preceding sentence, if notice of the inaccuracy or breach thereof giving rise to such right of indemnity shall have been given
in reasonable detail to the party against whom such indemnity may be sought prior to such time.

 

7.2
Indemnification 

 

(a)
Indemnification By Company.
Subject to the other terms and conditions of this Article VII, the Company shall indemnify and defend Purchaser and its Affiliates
and their respective Representatives (collectively, the “Purchaser Indemnitees”) against, and shall hold each
of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by,
or imposed upon, the Purchaser Indemnitees based upon, arising out of, with respect to or by reason of:

 

(i)
any inaccuracy in or breach of any of the representations
or warranties of the Company contained in this Agreement or in any certificate or instrument delivered by or on behalf of the
Company pursuant to this Agreement; or

 

(ii)
any breach or non-fulfillment of any covenant,
agreement or obligation to be performed by the Company pursuant to this Agreement.

 

(b)
Indemnification By Purchaser.
Subject to the other terms and conditions of this Article VII, the Purchaser shall indemnify and defend the Company against, and
shall hold the Company harmless from and against, and shall pay and reimburse the Company for, any and all Losses incurred or
sustained by, or imposed upon, the Company based upon, arising out of, with respect to or by reason of:

 

(i)
any inaccuracy in or breach of any of the representations
or warranties of the Purchaser contained in this Agreement or in any certificate or instrument delivered by or on behalf of the
Purchaser pursuant to this Agreement; or

 

(ii)
any breach or non-fulfillment of any covenant,
agreement or obligation to be performed by the Purchaser pursuant to this Agreement.

 

7.3
Procedures.
The party seeking indemnification under Section 7.2 agrees to give reasonably prompt notice to the party against whom indemnity
is sought of the assertion of any claim, or the commencement of any suit, action or proceeding in respect of which indemnity may
be sought under such Section. The indemnifying party may at its election participate in and control the defense of any such suit,
action or proceeding at its own expense; provided that the indemnified party may participate, at its own expense, in the defense
of such claim. The indemnifying party shall not be liable under Section 7.2 for any settlement effected without its consent of
any claim, litigation or proceeding in respect of which indemnity may be sought hereunder.

 

    	-12-

     

    

 

7.4
Certain Limitations.
For purposes of this Article VII, any inaccuracy in or breach of any representation or warranty and the amount of a party’s
Losses shall be determined without regard to any materiality, material adverse effect or other similar qualification contained
in or otherwise applicable to such representation or warranty.

 

7.5
Payments.
Once a Loss is agreed to by the Company and the Purchaser or finally adjudicated to be payable pursuant to this Article VII, the
Company or the Purchaser, as the case may be, shall satisfy its obligations within five (5) Business Days of such agreement or
final, non-appealable adjudication by wire transfer of immediately available funds.

 

7.6
Tax Treatment of Indemnification Payments.
All indemnification payments made under this Agreement shall
be treated by the parties as an adjustment to the Purchase Price for tax purposes, unless otherwise required by Law.

 

7.7
Effect of Investigation.
Neither the representations, warranties and covenants of the Company, nor the right to indemnification of any Purchaser Indemnitee
making a claim under this Article VII with respect thereto, shall be affected or deemed waived by reason of any investigation
made by or on behalf of an Purchaser Indemnitee (including by any of its Representatives) or by reason of the fact that an Purchaser
Indemnitee or any of its Representatives knew or should have known that any such representation or warranty is, was or might be
inaccurate or by reason of an Purchaser Indemnitee’s waiver of any closing condition.

 

8.
Miscellaneous.

 

8.1
Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the
choice of law provisions thereof, and the federal laws of the United States.

 

8.2
Jurisdiction. Except
as otherwise expressly provided in this Agreement, the parties hereto agree that any suit, action or proceeding seeking to enforce
any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated
hereby may only be brought in a state or federal court of competent jurisdiction sitting in New York, New York and each of the
parties hereby consents to the non-exclusive jurisdiction of such courts (and of the appropriate appellate courts therefrom) in
any such suit, action or proceeding. Process in any such suit, action or proceeding may be served on any party anywhere in the
world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service
of process on such party as provided in Section 8.10 shall be deemed effective service of process on such party.

 

8.3
Successors and Assigns.
Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors, and administrators of the parties hereto. Notwithstanding the foregoing, the Company may not assign
this Agreement or any rights or obligations hereunder without the prior written consent of the Purchaser.

 

    	-13-

     

    

 

8.4
No Third Party Beneficiaries. This
Agreement shall not confer any rights or remedies upon any Person other than the parties hereto and their respective heirs, personal
legal representatives, successors and permitted assigns and the Purchaser Indemnitees.

 

8.5
Entire Agreement.
This Agreement and the exhibits hereto, and the other documents delivered pursuant hereto, constitute the full and entire understanding
and agreement among the parties with regard to the subjects hereof and no party shall be liable or bound to any other party in
any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein.

 

8.6
Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

8.7
Severability.
In the event any provision of this Agreement shall be invalid, illegal, or unenforceable, it shall to the extent practicable,
be modified so as to make it valid, legal and enforceable and to retain as nearly as practicable the intent of the parties, and
the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

8.8
Amendment and Waiver.
Except as otherwise provided herein, any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance, either retroactively or prospectively, and either for a specified
period of time or indefinitely), with the written consent of the Company and the Purchaser.

 

8.9
Fees and Expenses.
Except as otherwise set forth herein, the Company and Purchaser shall each bear its own expenses and legal fees incurred in connection
with the negotiation, execution, delivery and performance of this Agreement. The Company will pay up to $75,000 of the Company’s
legal and other expenses with respect to this Agreement and the transactions contemplated hereby from the proceeds of the sale
of the Shares.

 

8.10
Notices.
All notices, requests, consents and other communications hereunder shall be in writing, shall be delivered, if within the United
States, by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and
shall be addressed as follows, or to such other address or addresses as may have been furnished in writing by a party to another
party pursuant to this paragraph:

 

	 	●	if
    to the Company, to the address of the Company’s principal office set forth on the first page of this Agreement, Attention:
    Christopher Reinhard Chief Executive Officer, e-mail: creinhard@angionetics.com with a copy to Jamie Mercer, JMercer@sheppardmullin.com.
    
	 	 	 
	 	●	if
    to the Purchaser, to the address of the Purchaser’s principal office set forth on the first page of this Agreement with
    a copy to Carlton Asher, Esq., asherlaw@att.net 110 E. 59th Street New York, New York 10022.

 

8.11
Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be
deemed to be one and the same agreement. Delivery of a signed Agreement by reliable electronic means, including facsimile, email,
or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (including DocuSign) shall be an effective method
of delivering the executed Agreement. This Agreement may be stored by electronic means and either an original or an electronically
stored copy of this Agreement can be used for all purposes, including in any proceeding to enforce the rights and/or obligations
of the parties to this Agreement.

 

[The
Remainder of this Page is Blank; Signature Pages Follow]

 

    	-14-

     

    

 

In
witness whereof, the foregoing Preferred Stock Purchase Agreement is hereby executed as of the date first above written.

 

	 	Gene
    Biotherapeutics, Inc.
	 	 
	 	By:	/s/
    Christopher Reinhard
	 	Name:	Christopher
    Reinhard
	 	Title:	Chief
    Executive Officer

 

    	-15-

     

    

 

In
witness whereof, the foregoing Preferred Stock Purchase Agreement is hereby executed as of the date first above written.

 

	 	Nostrum
    Pharmaceuticals LLC
	 	Name
    of Investor
	 	 
	 	By:	/s/
    Nirmal Mulye
	 	Name:	Nirmal
    Mulye, Phd
	 	Title:	President

 

    	-16-

     

    

 

Schedule
A

 

Definitions

 

“Action”
means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,
citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether
at law or in equity.

 

“Affiliate”
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by,
or is under common control with, such Person. The term “control” (including the terms “controlled by”
and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise
..

 

“Board”
means the board of directors of the Company.

 

“Business
Day” means any day except Saturday, Sunday or any other day on which commercial banks located in New York, New York
are authorized or required by Law to be closed for business.

 

“Contracts”
means all contracts, leases, deeds, mortgages, licenses, instruments, notes, loans, commitments, undertakings, indentures, joint
ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.

 

“Conversion
Shares” means the shares of Common Stock into which the Shares shall be convertible.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Dollars
or $” means the lawful currency of the United States.

 

“Encumbrance”
means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option,
security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including
any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

“FDA”
means the U.S. Food and Drug Administration of the United States Department of Health and Human Services or any successor agency
thereof performing similar functions.

 

“FDCA
means the Federal Food, Drug and Cosmetic Act of 1938, as amended (the “FDCA”) and the regulations of the FDA
promulgated thereunder.

 

“Governmental
Authority” means any federal, state, local or foreign government or political subdivision thereof, or any agency or
instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory
authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority
have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

 

    	-17-

     

    

 

“Governmental
Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.

 

“Knowledge
of the Company or the Company’s Knowledge” or any other similar knowledge qualification, means the actual or constructive
knowledge of any director or officer of the Company, after due inquiry.

 

“Law”
means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement
or rule of law of any Governmental Authority.

 

“Losses”
means losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of
whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and
the cost of pursuing any insurance providers; provided, that “Losses” shall not include punitive damages,
except in the case of fraud or to the extent actually awarded to a Governmental Authority or other third party.

 

“Permits”
means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights
obtained, or required to be obtained, from Governmental Authorities.

 

“Person”
means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated
organization, trust, association or other entity.

 

“Representative”
means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants
and other agents of such Person.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“Securities”
means, collectively, the Shares and the Conversion Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.

 

“Subsidiary”
means the following subsidiaries of the Company: Angionetics, Inc. a Delaware corporation and Activation Therapeutics, Inc.
a Delaware corporation.

 

    	-18-Exhibit
10.2 

 

REAFFIRMATION
AND RATIFICATION AGREEMENT

 

April
10, 2020

GENE
BIOTHERAPEUTICS, iNC.

11568 Sorrento Valley Road

Suite Fourteen

San Diego, CA 92121

 

Ladies
and Gentlemen:

 

Shanxi
Taxus Pharmaceuticals Co., Ltd. (“Shanxi”) executed and delivered to Gene Biotherapeutics, Inc. (“Company”)
a Restructuring Plan Settlement Letter dated December 19, 2019 (“Letter Agreement”) pursuant to which Shanxi
agreed to cancel its $600,000 equity subscription with respect to the Company and treat the payment as an upfront license fee
on the Excellagen and Generx licenses described in the Letter Agreement.

 

Concurrently
herewith, Shanxi and Activation Therapeutics, Inc., a wholly-owned subsidiary of the Company (“Activation”),
are entering into a certain Tri-Party Excellagen Agreement with respect to Excellagen (the “Excellagen License Agreement”)
and Shanxi and Angionetics, Inc., a majority-owned subsidiary of the Company (“Angionetics”), are entering
into a certain Distribution and License Agreement with respect to Generx (the “Generx License Agreement and, together
with the Excellagen License Agreement, the “Definitive License Agreements”). To induce the Company to cause
Activation and Angionetics to enter the Definitive License Agreements, Shanxi for and on behalf of itself and its present or former
parents, subsidiaries, affiliates, officers, managers, members, successors and assigns (“Releasor Parties”)
hereby:

 

(a)
acknowledges, ratifies, reaffirms and confirms that any and all rights, agreements, arrangements or commitments of any kind or
character relating to the capital stock of the Company or any of its subsidiaries (including without limitation, Angionetics and
Activation) or obligating the Company or any of its subsidiaries (including, without limitation, Angionetics and Activation) to
issue or sell any shares of capital stock of, or any other interest in, the Company or such subsidiary, are terminated and cancelled
without any further force or effect; and

 

(b)
releases, remises, acquits and forever discharges the Company, Angionetics, Activation, their subsidiaries and affiliates and
each of their respective employees, agents, representatives, consultants, attorneys, fiduciaries, officers, directors, partners,
predecessors, successors and assigns, subsidiary corporations, parent corporations, and related corporate divisions (all of the
foregoing hereinafter called the “Released Parties”), from any and all actions and causes of action, judgments,
executions, suits, debts, claims, demands, liabilities, obligations, damages and expenses of any and every character, known or
unknown, direct and/or indirect, at law or in equity, of whatsoever kind or nature (the “Claims”), for or because
of any matter or things done, omitted or suffered to be done by any of the Released Parties prior to and including the date of
execution hereof, whether such Claims are matured or unmatured or known or unknown, excluding Claims arising out of a breach of
any representations warranties or covenants contained in the Definitive License Agreements.

 

    	 

     

    

 

It
is the intention of Shanxi that this letter agreement and the release set forth above shall constitute a full and final accord
and satisfaction of all Claims they may have or hereafter be deemed to have against the Released Parties as set forth herein.
In furtherance of this intention, Shanxi expressly waives any statutory or common law provision that would otherwise prevent the
release set forth above from extending to Claims that are not currently known or suspected to exist in any Releasor’s favor
at the time of executing this letter agreement and which, if known by Releasors or any of them, might have materially affected
the agreement set forth herein. In furtherance of this intention, Shanxi hereby expressly waives any and all rights and benefits
conferred upon you by Section 1542 of the California Civil Code, which provides:

 

A
general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her
favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with
the debtor or released party.

 

Shanxi
understands, acknowledges and agrees that (a) the release set forth above may be pleaded as a full and complete defense and may
be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted
in breach of the provisions of such release; (b) no fact, event, circumstance, evidence or transaction which could now be asserted
or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set
forth above; and (c) it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Released Party on the
basis of any Claim waived, released and discharged by such Releasor Party in this letter agreement. If a Releasor Party or any
of its successors, assigns or other legal representatives violates the covenant set forth in above, Shanxi agrees to pay, in addition
to such other damages as any Released Party may sustain as a result of such violation, all attorneys’ fees and costs incurred
by any Released Party as a result of such violation

 

[Remainder
of Page Intentionally Left Blank]

 

    	 

     

    

 

This
Reaffirmation and Ratification Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
heirs, administrators, executors, successors and assigns and shall be governed by and construed in accordance with the laws of
the State of New York. Any signature delivered by a party by facsimile or electronic transmission shall be deemed to be an original
signature hereto.

 

	 	Very
    truly yours,
	 	 
	 	SHANXI
    TAXUS PHARMACEUTICALS CO., LTD.
	 	 
	 	BY:	/s/
    Jiayue Zhang               
	 	NAME:	Jiayue
    Zhang
	 	TITLE:	Chairman
    and President

 

	 	Accepted
    and Agreed as of             , 2020:
	 	 
	 	GENE
    BIOTHERAPEUTICS, INC.
	 	 
	 	BY:	/s/
    Christopher Reinhard            
	 	NAME:	Christopher
    Reinhard
	 	TITLE
    :	Chief
    Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]